For a consideration of USD 142.9 million
Jubilant Pharmova announced that its wholly owned subsidiary, Jubilant Pharma, Singapore (JPL) has divested its entire 25.8% stake in Sofie Biosciences Inc., USA (Sofie). JPL has received USD 115.9 million as a part of the consideration. An additional USD 1.2 million is held in escrow account for any post-closing adjustments. Besides this consideration, the sum of up to USD 25.8 million may be received by JPL being contingent upon achievement of certain future milestones.
JPL plans to use the proceeds to reduce leverage and balance for capex and other corporate purposes.
JPL invested USD 25 million in Sofie. In Jan'2024, Sofie entered into a definitive merger agreement with private equity funds managed by Trilantic Capital Partners, North America, a US private equity firm. Consequently, JPL planned to sell its entire stake in Sofie for an aggregate proceeds of about USD 142.9 million. The merger transaction closed on 31 May 2024.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app